Pharmarise Holdings Corporation (TYO:2796)
Japan · Delayed Price · Currency is JPY 490.00
+6.00 (1.24%)
Jul 10, 2026, 3:30 PM JST
Pharmarise Holdings Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
| 69,512 | 63,508 | 54,466 | 52,030 | 51,608 | |
Revenue Growth (YoY) | 9.45% | 16.60% | 4.68% | 0.82% | -1.37% |
Cost of Revenue | 60,053 | 54,542 | 46,017 | 43,896 | 43,491 |
Gross Profit | 9,459 | 8,966 | 8,449 | 8,134 | 8,117 |
Selling, General & Admin | 8,512 | 4,860 | 4,371 | 3,728 | 3,525 |
Amortization of Goodwill & Intangibles | - | 763 | 557 | 635 | 700 |
Other Operating Expenses | - | 3,048 | 2,605 | 2,332 | 2,371 |
Operating Expenses | 8,512 | 8,671 | 7,533 | 6,695 | 6,596 |
Operating Income | 947 | 295 | 916 | 1,439 | 1,521 |
Interest Expense | -285 | -178 | -66 | -55 | -65 |
Interest & Investment Income | 13 | 10 | 1 | 2 | 2 |
Other Non Operating Income (Expenses) | 39 | -10 | -19 | 44 | 58 |
EBT Excluding Unusual Items | 714 | 117 | 832 | 1,430 | 1,516 |
Gain (Loss) on Sale of Investments | - | 7 | 19 | 30 | - |
Gain (Loss) on Sale of Assets | 18 | 20 | -1 | -4 | 2 |
Asset Writedown | -55 | -258 | -296 | -393 | -218 |
Other Unusual Items | 21 | 124 | -411 | -14 | 21 |
Pretax Income | 698 | 10 | 143 | 1,049 | 1,321 |
Income Tax Expense | 590 | 390 | 485 | 702 | 864 |
Earnings From Continuing Operations | 108 | -380 | -342 | 347 | 457 |
Minority Interest in Earnings | 6 | 13 | -9 | -14 | -10 |
Net Income | 114 | -367 | -351 | 333 | 447 |
Net Income to Common | 114 | -367 | -351 | 333 | 447 |
Net Income Growth | - | - | - | -25.50% | 4.93% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 9 | 9 |
Shares Outstanding (Diluted) | 12 | 11 | 11 | 12 | 12 |
Shares Change (YoY) | 5.29% | 7.58% | -15.61% | 0.59% | 0.20% |
EPS (Basic) | 9.95 | -32.42 | -33.35 | 35.42 | 47.90 |
EPS (Diluted) | 9.62 | -32.42 | -33.35 | 26.86 | 36.22 |
EPS Growth | - | - | - | -25.83% | 4.70% |
Free Cash Flow | 2,582 | 674 | 2,242 | 2,140 | 334 |
Free Cash Flow Per Share | 216.61 | 59.53 | 213.04 | 171.61 | 26.94 |
Dividend Per Share | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 |
Gross Margin | 13.61% | 14.12% | 15.51% | 15.63% | 15.73% |
Operating Margin | 1.36% | 0.46% | 1.68% | 2.77% | 2.95% |
Profit Margin | 0.16% | -0.58% | -0.64% | 0.64% | 0.87% |
Free Cash Flow Margin | 3.71% | 1.06% | 4.12% | 4.11% | 0.65% |
EBITDA | 2,552 | 1,788 | 2,086 | 2,663 | 2,829 |
EBITDA Margin | 3.67% | 2.81% | 3.83% | 5.12% | 5.48% |
D&A For EBITDA | 1,605 | 1,493 | 1,170 | 1,224 | 1,308 |
EBIT | 947 | 295 | 916 | 1,439 | 1,521 |
EBIT Margin | 1.36% | 0.46% | 1.68% | 2.77% | 2.95% |
Effective Tax Rate | 84.53% | 3900.00% | 339.16% | 66.92% | 65.41% |